Cite
Thiem U, Soellradl I, Robl B, et al. The effect of phosphate binder therapy with sucroferric oxyhydroxide on calcification propensity in chronic haemodialysis patients: a randomized, controlled, crossover trial. Clin Kidney J. 2020;14(2):631-638doi: 10.1093/ckj/sfaa154.
Thiem, U., Soellradl, I., Robl, B., Watorek, E., Blum, S., Dumfarth, A., Marculescu, R., Pasch, A., Haller, M. C., & Cejka, D. (2021). The effect of phosphate binder therapy with sucroferric oxyhydroxide on calcification propensity in chronic haemodialysis patients: a randomized, controlled, crossover trial. Clinical kidney journal, 14(2), 631-638. https://doi.org/10.1093/ckj/sfaa154
Thiem, Ursula, et al. "The effect of phosphate binder therapy with sucroferric oxyhydroxide on calcification propensity in chronic haemodialysis patients: a randomized, controlled, crossover trial." Clinical kidney journal vol. 14,2 (2021): 631-638. doi: https://doi.org/10.1093/ckj/sfaa154
Thiem U, Soellradl I, Robl B, Watorek E, Blum S, Dumfarth A, Marculescu R, Pasch A, Haller MC, Cejka D. The effect of phosphate binder therapy with sucroferric oxyhydroxide on calcification propensity in chronic haemodialysis patients: a randomized, controlled, crossover trial. Clin Kidney J. 2020 Oct 28;14(2):631-638. doi: 10.1093/ckj/sfaa154. eCollection 2021 Feb. PMID: 33623689; PMCID: PMC7886583.
Copy
Download .nbib